Turku-based Pharmatest Services Ltd participated in an international project with promising results
The Turku-based company Pharmatest Services Ltd has identified 15 new compounds suitable for breast and prostate cancer drugs. The compounds were identified with newly developed methods using cancer cell lines that allow decreasing considerably animal testing in future cancer drug development.
The Turku-based company Pharmatest Services Ltd participated in a 3-year research project "DISC-SCREEN" funded by the Eurostars program of EU. In the project Pharmatest developed new testing methods where cancer cell lines are used for estimating efficacy of cancer drug candidates. Pharmatest was able to use the methods for identifying 15 patentable drug candidates from a large group of compounds modeled in silico by the Romanian partner CCTI:n (Centrul Pentru Cooperare Tehnologica si Industriala) and synthesized by the Spanish partner IUCT:n (Institut Universitari De Ciència I Tecnologia). The compounds were more efficient and safer than the best cancer drugs currently on the markets when tested in various breast and prostate cancer cell lines.
Pharmatest, IUCT and CCTI have started negotiations with a drug development company for utilizing and patenting the results. The companies predict to start more detailed preclinical tests with 3-5 compounds within the next three months and get at least one compound to clinical studies within the next two years.
MORE INFORMATION FROM:
Pharmatest Services Ltd, CEO Jussi Halleen, phone +358 50 380 9551
About Pharmatest Services Oy
Pharmatest Services OyItäinen Pitkäkatu 4 C
20520 Turku
info(at)pharmatest.com, +358 2 278 4700http://www.pharmatest.com
Subscribe to releases from Pharmatest Services Oy
Subscribe to all the latest releases from Pharmatest Services Oy by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Pharmatest Services Oy
Pharmatest Services investoi uusimpaan luuston kuvantamisteknologiaan17.10.2016 09:59:47 EEST | Tiedote
Turkulainen Pharmatest Services Oy on hankkinut kaksi uusinta teknologiaa käyttävää tutkimuslaitetta luuston kuvantamiseen, Brukerin korkean resoluution in vivo mCT laitteen SkyScan 1276 sekä DatecMedicon digitaalisen röntgenlaitteen Faxitron UltraFocus DXA.
Pharmatest Services Oy:lle rahoitusta kahteen EU-hankkeeseen12.10.2015 13:18:38 EEST | Tiedote
Pharmatest Services Oy on saanut yhdessä eurooppalaisten partnereidensa kanssa rahoitusta kahteen tuotekehitysprojektiinsa. Toinen rahoituksista liittyy EU:n Eurostars-ohjelmaan, ja toinen EU:n EuroTransBio-ohjelmaan. Molemmat rahoitettavat hankkeet ovat 3-vuotisia, ja Pharmatest kehittää niissä uusia syöpälääkekehitykseen soveltuvia prekliinisiä tehokkuustutkimusmalleja.
Pharmatest Services Oy avaa USA:n myyntitoimiston Cambridgeen18.2.2013 08:36:11 EET | Tiedote
Turkulainen Pharmatest Services Oy (Pharmatest) on avannut uuden USA:n myyntitoimiston Bostonin lähelle Cambridgeen. Uusi toimisto parantaa merkittävästi Pharmatestin mahdollisuuksia asiakaskontaktointiin USA:ssa, sillä useilla Pharmatestin potentiaalisilla asiakkailla on toimipisteet Bostonin alueella.
Pharmatest Services Ltd opens US sales office in Cambridge, MA18.2.2013 08:36:10 EET | Press release
Turku, Finland-based Pharmatest Services Ltd (Pharmatest) has opened a new US sales office in Cambridge, MA near Boston. The new office provides an excellent opportunity for Pharmatest to contact and serve customers, with a large number of potential customers located in the Boston area.
Pharmatest Services Ltd became preferred provider of Valirx Plc15.10.2012 13:41:54 EEST | Tiedote
The Turku-based company Pharmatest Services Ltd (Pharmatest) has signed a Master Service Agreement with the London AIM-listed cancer drug development company Valirx Plc (Valirx). The agreement makes Pharmatest preferred provider of preclinical efficacy testing services for Valirx in its cancer drug development programs.